Atropine challenge

Phase 3Small molecule

EEmory University

Atropine challenge is one of 4 small molecule programs targeting Achalasia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AchalasiaRecruiting

AchalasiaPhase 3

Recruiting

Competition

Competitive Landscape

5 competitors in Achalasia

#DrugCompanyPhaseTrials

Botox

RRevance Therapeutics, Inc.

Approved

2 2

Avycaz

PPhiladelphia Eye Associates

Atropine challenge

1 4

Second Generation Cephalosporin

SShanghai Zhongshan Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

ApprovedRecruiting

Achalasia

NCT04641702

Clinical

Trials by Indication[1]

Achalasia1 trial

Comprehensive Assessment of Histopathologic and Physiologic Profile in Esophageal Motility Disorders

Recruiting·EEmory University·Approved·NCT04641702·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Atropine challenge. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Atropine challenge compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Atropine challenge. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Emory University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEmory University

Atropine challenge

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Achalasia1 trial

References

Drug Info

Quick Facts

Related News